Details

Autor(en) / Beteiligte

• Cao, Shan
• Zhou, Gan
• Ou-YANG, Dong-sheng
• Wu, Hui-zi
• Xiao, Kui
• Chen, Yao
• Guo, Dong
• Fan, Lan
• Tan, Zhi-rong
• Hu, Hai-tang
• Qin, Xiang-hong
• Zhou, Hong-hao
• Zhang, Wei

Titel

Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy

Ist Teil von

• Acta pharmacologica Sinica, 2012-08, Vol.33 (8), p.1095-1100

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Aim： To investigate the drug interactions between ilaprazole, a new proton pump inhibitor, and clarithromycin following ilaprazole, clarithromycin and amoxicillin combination therapy. Methods： Twelve healthy Chinese volunteers were recruited in a randomized, open-label, 3-period crossover study. All subjects were administered ilaprazole （5 mg）, clarithromycin （500 mg） or a triple therapy, including ilaprazole （5 mg）, clarithromycin （500 mg） and amoxicillin （1 g）, twice daily for 6 consecutive days. On the 7th day, the drugs were given once, and blood samples were collected and analyzed using a well-validated HPLC/MS/MS method. Results： Following the triple therapy, the peak concentration （Cmax） and the area under the concentration-time curve from 0 h to 12 h （AUC0→12） of ilaprazole were significantly decreased, as compared with the single medication group （Cmax： 1025.0±319.6 vs 1452.3_±324.6 ng/mL; AUC0→12：9777.7±3789.8 vs 11363.1±3442.0 ng.h/mL）. Similar changes were found for ilaprazole sulfone （Cmax： 5.9±0.5 vs 9.3±1.7 ng/mL; AUC0→12：201.4±32.1 vs 277.1±66.2 ng.h/mL）. The triple therapy significantly elevated the Cmax of clarithromycin （3161.5±702.2 vs 2541.9±476.2 ng/mL）. Conclusion： The H pylori eradication therapy with clarithromycin, amoxicillin and ilaprazole may cause pharmacokinetic interactions that decrease the amount of ilaprazole and its metabolites and elevate that of clarithromycin.